PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo,
Inc. (DSI) announced today that John P.
Gargiulo has been appointed President and CEO of the
company. Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is retiring after leading
Daiichi Sankyo Group's U.S. commercial operations for the past 14
years.
"John's experiences within the pharmaceutical industry for the
past 25 years have prepared him well for his new role and
responsibility," said Joseph
Pieroni, former President and CEO of Daiichi Sankyo, Inc.
"He has been instrumental in building and shaping the company since
its inception in 1996, and has touched nearly every aspect of our
business operations. His broad industry experience enabled him to
learn and grow the commercial operations organization."
Mr. Gargiulo most recently served as Senior Vice President of
Commercial Operations, where he oversaw U.S. Marketing, Supply
Chain, Managed Markets and New Product Planning. After joining the
predecessor organization, Sankyo, in 1995, Gargiulo was
instrumental in advancing DSI from a joint venture with Parke-Davis
to its current status as a leader in hypertension therapy and with
an emerging presence in thrombosis and oncology.
"Joe has been a great leader, and has made DSI a successful
company by driving excellence through innovation, integrity and
accountability -- and by modeling these core company values
himself," said Gargiulo, President and CEO of Daiichi Sankyo, Inc.
"I am excited about leading DSI through our next company
milestones, and fostering a continuing vision of employee
excellence that will drive DSI growth and success."
Prior to joining DSI, Gargiulo held several positions at Lederle
Laboratories. He currently serves on the Board of Directors of the
national industry trade association, the Pharmaceutical Research
and Manufacturers Association (PhRMA), and the National
Pharmaceutical Council (NPC), an industry trade group focused on
evidence-based medicine.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply
of innovative pharmaceutical products to address the diversified,
unmet medical needs of patients in both mature and emerging
markets. While maintaining its portfolio of marketed
pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments
for thrombotic disorders and focused on the discovery of novel
oncology and cardiovascular-metabolic therapies. Furthermore, the
Daiichi Sankyo Group has created a "Hybrid Business Model," which
will respond to market and customer diversity and optimize growth
opportunities across the value chain. For more information, please
visit www.daiichisankyo.com
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the
Daiichi Sankyo Group. For more information on Daiichi Sankyo,
Inc., please visit www.dsi.com.
SOURCE Daiichi Sankyo, Inc.